ADPT Diagnostics · Cancer diagnostics · MRD testing · Biotech tools · Thesis updated August 4, 2026

clonoSEQ growth carries the company toward a business split

MRD revenue was $66.2 million in Q2 2026, up 33% from a year earlier.
clonoSEQ test volume grew 43% in Q2 2026, showing strong demand from doctors and drug companies.
MRD made up 92% of Q2 2026 revenue, tying the company to one core product.
The company announced plans to separate the MRD and Immune Medicine businesses by year-end 2026.
Adaptive is winding down its research-use-only Adaptive Immunosequencing service to focus on data licensing.
The company issued $345 million in new convertible notes to extinguish a legacy revenue interest liability.

01 Running thesis

A sharper focus and a planned split

Adaptive is stripping down its operations to focus on what works best. The main story is clonoSEQ, a test for minimal residual disease that detects tiny amounts of cancer left after treatment. In Q2 2026, MRD revenue grew 33% and clonoSEQ volume grew 43%. The segment now makes up 92% of the company total revenue.

The bull case is that clonoSEQ is executing flawlessly and will soon trade on its own merits. In June 2026, the company announced its intention to separate the fast-growing, high-margin MRD business from the early-stage Immune Medicine segment by year-end 2026. This move, combined with extinguishing legacy revenue liabilities using new debt, could improve long-term cash flow.

The bear case centers on the risks of this transition and heavy product concentration. The planned separation and the wind-down of the Adaptive Immunosequencing service highlight the struggles of the Immune Medicine segment since the Genentech collaboration ended. The separation could be costly and distracting to management.

Investors are currently valuing the company largely for its MRD growth. A new $345 million convertible debt issue adds leverage just as the company prepares for a complex corporate restructuring.

Aug 2026▲Q2 2026 results revealed plans to separate the MRD and Immune Medicine businesses by year-end. MRD revenue continued to grow fast, reaching 92% of total revenue.

May 2026▲Q1 2026 confirmed the MRD thesis. MRD revenue grew 53%, clonoSEQ volume grew 41%, and management raised 2026 MRD revenue guidance to $260 million to $270 million.

May 2026→The Q1 2026 filing showed Immune Medicine revenue down 57% after the Genentech wind-down. This did not change the main thesis, but it made the concentration risk clearer.

Feb 2026▲The FY2025 filing showed MRD revenue of $212.3 million, up 46%, with clonoSEQ test volume up 39%. The new Medicare price also increased by 17% from the prior rate.

Nov 2025▼The Genentech collaboration was terminated, removing a major Immune Medicine partner. A one-time revenue benefit helped GAAP profit in the quarter, but it was not a normal run-rate.

Aug 2025▲Q2 2025 showed MRD revenue growth of 42% and the segment reached positive Adjusted EBITDA for the first time. Company-wide cash burn also improved.

May 2025▲Q1 2025 showed MRD revenue growth of 34% and clonoSEQ volume growth of 36%. The net loss narrowed versus the prior year.

Mar 2025→The FY2024 filing showed Adaptive becoming more of a pure MRD diagnostics company. It also added risk from the FDA new rules for laboratory developed tests.

02 Business model

Restructuring toward pure diagnostics

Adaptive historically made money in two segments: MRD and Immune Medicine. MRD is the core business. It sells clonoSEQ testing to doctors who monitor blood cancers and to biopharma companies that use the test in drug studies. This diagnostic side has consistent growth and clear pricing.

The Immune Medicine segment previously sold immunosequencing research services, data licensing, and discovery partnerships. However, in July 2026, the company decided to wind down its research-use-only pharma services to focus exclusively on its target discovery platform and data models.

The biggest change to the model is the plan to separate these two segments entirely by the end of 2026. The goal is to let the profitable MRD business operate without funding the early-stage Immune Medicine research.

To clean up its balance sheet ahead of the split, Adaptive issued $345 million in convertible notes and used $156.9 million of the proceeds to extinguish a legacy revenue interest liability. The model relies heavily on clonoSEQ volume rising faster than the new interest and restructuring costs.

03 Product portfolio

What Adaptive sells

Growth engine

clonoSEQ for clinical care

clonoSEQ is the main product. It helps doctors detect and monitor tiny traces of cancer in multiple myeloma and other lymphoid cancers.

Growth engine

clonoSEQ for biopharma trials

Drug companies use clonoSEQ testing in studies to measure how well cancer drugs clear disease.

Option

TCR discovery and antigen maps

Adaptive uses immune receptor data to connect T cells with the targets they recognize. This includes data licensing agreements with partners like Pfizer.

Steady

Adaptive Immunosequencing

This research-use service reads immune receptor data. The company is winding down this offering in the second half of 2026.

04 Business segments

MRD takes over the mix

MRD92%growing fast

Immune Medicine8%declining

The mix is from the three months ended June 30, 2026. MRD was 92% of revenue, making clonoSEQ the primary value driver ahead of the planned separation.

05 Risk factors

What could go wrong

Execution of the corporate split

High impact · Medium odds

The planned separation of the MRD and Immune Medicine segments by year-end 2026 is complex. It could incur high costs, distract management, or fail to find a viable path for the Immune Medicine assets.

We watchUpdates on the separation structure and associated restructuring costs.

New debt burden

Medium impact · Medium odds

The company issued $345 million in convertible notes in June 2026. This increases leverage before the separation is complete and could limit future cash flow flexibility.

We watchInterest expenses and how the debt is apportioned between the separated entities.

clonoSEQ concentration

High impact · High odds

MRD made up 92% of Q2 2026 revenue. That means one product line drives almost the whole company. Any slowdown in clonoSEQ volumes would severely damage the core business valuation.

We watchQuarterly clonoSEQ test volume growth and clinical adoption rates.

Payer and regulatory changes

Medium impact · Medium odds

The FDA final rule on Laboratory Developed Tests will phase out enforcement discretion over four years. This could subject clonoSEQ to more extensive requirements and increase compliance costs.

We watchFDA LDT compliance updates and Medicare reimbursement rates.

06 Quick answers

In one breath

What does Adaptive Biotechnologies do?

Adaptive reads immune-system data and sells tests based on that data. Its main product is clonoSEQ, a cancer monitoring test for minimal residual disease.

Why is clonoSEQ important?

clonoSEQ helps detect very small amounts of cancer left after treatment. In Q2 2026, the MRD segment built around clonoSEQ was 92% of Adaptive revenue.

Is the company splitting up?

Yes. In June 2026, Adaptive announced a plan to separate its MRD and Immune Medicine businesses by the end of 2026.

What happened to the immunosequencing service?

Adaptive announced in July 2026 that it is winding down its research-use-only immunosequencing offering to focus purely on target discovery and data models.